RLT-PSMA
RLT-PSMA
Radioligand therapy prostate-specific membrane antigen
Emily MenendezRLT-PSMA | November 29, 2022
The effectiveness of PSMA PET was compared with conventional imaging & liver biopsy, and a radiomic model was also evaluated.
Read More
Emily MenendezRLT-PSMA | November 29, 2022
Between [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617, one treatment was more effective against PSMA-positive tumor xenografts.
Emily MenendezRLT-PSMA | November 29, 2022
68Ga-PSMA PET/CT may play a role in the detection of local or systemic disease in patients with prostate cancer.
Leah LawrenceRLT-PSMA | November 15, 2022
Improvements in PET–CT and repeat issues with ⁹⁹mTc supply have sparked interest in ¹⁸F-NaF PET–CT to detect bone ...
Emily MenendezRLT-PSMA | November 14, 2022
The phase 2 TheraP trial found that higher gallium-68–labeled PSMA-11-PET SUVmean had a higher chance of PSA response.
Emily MenendezRLT-PSMA | November 14, 2022
A radiotracer for prostate cancer biopsy punching can be applied to targeted biopsy to reduce the need for saturated biopsy.
Emily MenendezRLT-PSMA | November 14, 2022
Studies have investigated the effects of 177Lu-PSMA and 225Ac-PSMA RNT in mCRPC patients, with promising treatment results.
Emily MenendezRLT-PSMA | November 14, 2022
MicroRNAs can be used to develop new prostate cancer therapies and can target PSMA on the surface of prostate cancer cells.
Emily MenendezRLT-PSMA | October 31, 2022
The study is set to begin in 2023, and positive results could lead to a future marketing authorization for Illuccix in China.
Emily MenendezRLT-PSMA | October 31, 2022
Prostate cancer patients are at high risk of developing bone metastases, which can cause bone pain and skeletal fractures.
Emily MenendezRLT-PSMA | October 31, 2022
Illuccix is the first PSMA PET imaging agent to be approved for use in Canada and will be made available across the country.
Emily MenendezRLT-PSMA | October 31, 2022
Lu-177 was approved by the FDA in March 2022 and may have an advantage over other currently available PSMA treatments.
Daniel Tennenbaum, MDRLT-PSMA | October 25, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
Daniel Tennenbaum, MDRLT-PSMA | October 25, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
Emily MenendezRLT-PSMA | October 14, 2022
The phase 3 VISION trial showed that a higher PSA decline in mCRPC treated with 177Lu-PSMA-617 can predict better outcomes.
Emily MenendezRLT-PSMA | October 14, 2022
A study sought to determine the outcomes of localized PCa patients with suspected lymph node metastases on PSMA PET/CT.
Emily MenendezRLT-PSMA | October 14, 2022
While PSMA-617 has been found to extend survival in prostate cancer, PSMA-TO-1 may have a better survival benefit overall.
Leah LawrenceRLT-PSMA | October 12, 2022
ASCO has issued a Rapid Recommendation as an update to systemic therapy use of 177Lutetium-PSMA-617.
David Ambinder, MDVideo | September 27, 2022
An interview with Preston Sprenkle, MD, Associate Professor of Urology at Yale, on the clinical utility of PSMA imaging.
David Ambinder, MDVideo | September 27, 2022
An interview with Preston Sprenkle, MD, Associate Professor of Urology at Yale, on the clinical utility of PSMA imaging.
Advertisement
Advertisement